The MADIT II and COMPANION studies: will they affect uptake of device treatment?
作者信息
Morgan J M
出版信息
Heart. 2004 Mar;90(3):243-5. doi: 10.1136/hrt.2002.007807.
Abstract
摘要
相似文献
1
The MADIT II and COMPANION studies: will they affect uptake of device treatment?
Heart. 2004 Mar;90(3):243-5. doi: 10.1136/hrt.2002.007807.
2
Primary Prevention of Sudden Cardiac Death.
JAMA. 2019 Jul 9;322(2):161-162. doi: 10.1001/jama.2019.7662.
3
Saving lives and reducing inappropriate device therapy: the MADIT family of implantable cardioverter-defibrillator and cardiac resynchronization therapy trials.
Cardiol J. 2013;20(3):217-9. doi: 10.5603/CJ.2013.0064.
4
Newer Indications for ICD and CRT.
Cardiol Clin. 2014 May;32(2):181-90. doi: 10.1016/j.ccl.2013.12.004. Epub 2014 Feb 21.
5
Guidelines for device-based therapy of cardiac rhythm abnormalities.
Heart Rhythm. 2009 Mar;6(3):e1; author reply e2-3. doi: 10.1016/j.hrthm.2009.01.018. Epub 2009 Jan 21.
6
Implantable cardioverter defibrillators: therapy against Canada's leading killer.
CMAJ. 2004 Oct 26;171(9):1037-8. doi: 10.1503/cmaj.1041339.
7
Progress in implantable cardioverter-defibrillator therapy: Advancement beyond technology alone.
Trends Cardiovasc Med. 2015 Oct;25(7):612-3. doi: 10.1016/j.tcm.2015.02.009. Epub 2015 Feb 20.
8
Multicenter automatic defibrillator implantation trial: reduce inappropriate therapy (MADIT-RIT): background, rationale, and clinical protocol.
Ann Noninvasive Electrocardiol. 2012 Jul;17(3):176-85. doi: 10.1111/j.1542-474X.2012.00531.x.
9
American perspective: Comparing the AHA/ACC and ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.
J Nucl Cardiol. 2017 Dec;24(6):1904-1908. doi: 10.1007/s12350-017-1046-1. Epub 2017 Aug 22.
10
[Arrhythmias in heart insufficiency].
Internist (Berl). 2000 Mar;41(3):241-52. doi: 10.1007/s001080050500.
引用本文的文献
1
Prevention of sudden cardiac death in patients with chronic kidney disease.
BMC Nephrol. 2012 Dec 3;13:162. doi: 10.1186/1471-2369-13-162.
本文引用的文献
1
Implications of national guidance for implantable cardioverter defibrillation implantation in the United Kingdom.
Pacing Clin Electrophysiol. 2003 Jan;26(1P2):479-82. doi: 10.1046/j.1460-9592.2003.00076.x.
2
MADIT-II and its implications.
Eur Heart J. 2003 Jan;24(1):16-8. doi: 10.1016/s0195-668x(02)00627-9.
3
Comparison of medical therapy, pacing and defibrillation in heart failure (COMPANION) trial terminated early; combined biventricular pacemaker-defibrillators reduce all-cause mortality and hospitalization.
Int J Cardiol. 2003 Feb;87(2-3):119-20. doi: 10.1016/s0167-5273(02)00585-5.
4
Prevalence and incidence of arrhythmias and sudden death in heart failure.
Heart Fail Rev. 2002 Jul;7(3):229-42. doi: 10.1023/a:1020024122726.
5
QRS duration and mortality in patients with congestive heart failure.
Am Heart J. 2002 Jun;143(6):1085-91. doi: 10.1067/mhj.2002.122516.
6
Cardiac resynchronization in chronic heart failure.
N Engl J Med. 2002 Jun 13;346(24):1845-53. doi: 10.1056/NEJMoa013168.
7
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
N Engl J Med. 2002 Mar 21;346(12):877-83. doi: 10.1056/NEJMoa013474. Epub 2002 Mar 19.
8
9
The CARE-HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and end-points.
Eur J Heart Fail. 2001 Aug;3(4):481-9. doi: 10.1016/s1388-9842(01)00176-3.
10
Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay.
N Engl J Med. 2001 Mar 22;344(12):873-80. doi: 10.1056/NEJM200103223441202.
Zotero 插件